evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

200 questions · 203 findings · 8 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 82 · 40.4%GRADE not reported 10 · 4.9%Very low 25 · 12.3%Low 37 · 18.2%Moderate 35 · 17.2%High 14 · 6.9%

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Hand‐foot syndrome (grade ≥ 3) · platinum‐sensitive recurrent EOC

It is very uncertain whether summary of findings 1: PLD with chemotherapy changes hand‐foot syndrome (grade ≥ 3) compared with alternative combination chemotherapy (very low certainty).

1 finding from 1 review

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

Neurological (grade ≥ 3) · platinum‐sensitive recurrent EOC

It is very uncertain whether summary of findings 1: PLD with chemotherapy changes neurological (grade ≥ 3) compared with alternative combination chemotherapy (very low certainty).

1 finding from 1 review

Lifestyle interventions vs placebo or usual care

Overall survival (24 months) · weight reduction in obesity to improve survival in women with endometrial cancer

It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes overall survival (24 months) compared with usual care compared to placebo (very low certainty).

1 finding from 1 review

Lifestyle interventions vs placebo or usual care

Adverse events – musculoskeletal · weight reduction in obesity to improve survival in women with endometrial cancer

It is very uncertain whether summary of findings table ‐ Lifestyle intervention changes adverse events – musculoskeletal compared with usual care compared to placebo (very low certainty).

1 finding from 1 review

Lifestyle interventions vs placebo or usual care

Cardiovascular and metabolic event frequency (12 months) (Number of strokes, myocardial infarctions and hospitalisations for heart failure) · weight reduction in obesity to improve survival in women with endometrial cancer

Summary of findings table ‐ Lifestyle intervention showed no clear difference in cardiovascular and metabolic event frequency (6 months) compared with usual care compared to placebo (low certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

It is very uncertain whether summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy changes any severe adverse event (grade 3 or higher) (G3+ SevAE ) compared with placebo (maintenance therapy) (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

Overall survival (OS) · newly‐diagnosed EOC

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy showed no clear difference in overall survival (OS) compared with placebo (maintenance therapy) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

Progression‐free survival · newly‐diagnosed EOC

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy may leads to lower progression‐free survival (PFS) compared with placebo (maintenance therapy) (low certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone

Progression‐free survival · newly‐diagnosed EOC

It is very uncertain whether summary of findings table ‐ Newly‐diagnosed EOC: PARPi with… changes progression‐free survival (PFS) compared with chemotherapy alone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with chemotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi with… leads to higher any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy alone (high certainty).

1 finding from 1 review